|
|
|
| Study on formulation and technology of Cefpodoxime proxetil for Suspensions |
| Sun Yan, Zhang Suoqing, Hu Lijuan, Ma Yasong, Yang Hongshuo, Jia Yujie, Li Min |
| NCPC Hebei Huamin Pharmaceutical Corporation Ltd., Shijiazhuang 052165, China |
|
|
|
|
Abstract The formulation and technology of cefpodoxime proxetil for suspensions were determined. Using the dissolution, sedimentation volume, redispersibility and precipitation as the evaluation index, through inverstigting prescription factors which are, and optimize the formulation of cefpodoxime proxetil for suspension was adapted to design three factors and three levels. The studied and process factors included the following contents: type and dose of filling agent, and type dose of disintegrating agent, and binder concentration dring temperature and time of granulation, premixed time and adding order of flavouring. The results show that the determined formulation and technology of the cefpodoxime proxetil for suspension is feasible, and the product should be considered the consistent with the reference preparation in quality.
|
|
|
|
|
|
| 1 ] 邵长周,翟介明,何礼贤. 第3代口服头孢菌素-头孢泊肟酯[ J ]. 中国新药与临床杂杂志,2004( 23 )7:46 - 750.
[ 2 ] 国家药典委员会. 中华人民共和国药典(二部)[ S ]. 2015年版. 北京:中国医药科技出版社.
[ 3 ] 王春琴. 头孢泊肟酯胶囊的制备及质量标准研究[ D ]. 济南. 山东大学,2014.
[ 4 ] 涂胜昌. 第三代口服头孢菌素-头孢泊肟酯的研究进展[ J ]. 广东药学院学报,1999,15( 2 ):107 - 110.
[ 5 ] 张明发. 头孢泊肟酯的抗菌活性概述[ J ]. 上海医药,2005,26( 60 ):171 - 173.
[ 6 ] 郭惠娟,杜淑朋,宋维锋,等. 第3代头孢菌素-头孢泊肟酯的疗效及应用[ J ]. 河北医药,2008,30( 11 ):1 807.
[ 7 ] 邵长周,翟介明,何礼贤. 第3代口服头孢菌素-头孢泊肟酯[ J ]. 中国新药与临床杂杂志,2004( 23 ):746 - 750.
[ 8 ] 王震红,杨永刚,蒋 煜. 关于干混悬剂、混悬颗粒共性问题的探讨[ J ]. 中国药事,2007,21( 9 ):692 - 694.
[ 9 ] 鲍 骏,周汉明,陈 荣,等. 克拉霉素干混悬剂处方筛选与含量测定[ J ]. 医药导报,2009,28( 1 ):98 - 99.
[ 10 ] 罗明生,高天惠. 药剂辅料大全[ M ]. 成都:科学技术出版社,1995.
[ 11 ] 海南三叶美好制药有限公司. 头孢泊肟酯干混悬剂组合物及其制备方法[ P ].中国:101278914. B ,2010-06-02. |
|
|
|